Heart BMJ

JANUARY 10, 2024

Objective Catheter ablation of atrial fibrillation effectively reduces symptomatic burden. We investigated if patients with atrial fibrillation who undergo catheter ablation have lower risk for all-cause mortality or stroke than patients who are managed medically. ±1.5, vs 28.9%, p<0.001).

Atrial Fibrillation 52

Atrial Fibrillation Ablation Strokes Stroke 52

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability. The company has obtained U.S.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

Journal of Cardiovascular Electrophysiology

OCTOBER 30, 2024

Abstract Introduction The impact of repeated atrial fibrillation (AF) ablations on left atrial (LA) mechanical function remains uncertain, with limited long-term follow-up data. In the sub-study 2 with four MRIs, all three rates were negative, with reductions from postablation 1 to pre-ablation 2 ( r 22  =  − 13.3 ± 2.6%/year,

Atrial Fibrillation 40

Atrial Fibrillation Ablation Article 40

ADN Center of Excellence

MAY 17, 2024

It is with great pride that we announce the resounding success of ADN CoE' s AFib Ablation Training program, the second installment in our esteemed Ablation Series, held at the prestigious 9 Eylül University Heart Rhythm Management Centre.

AFIB 59

AFIB Atrial Fibrillation Ablation Heart Rhythm 59

ADN Center of Excellence

MAY 17, 2024

It is with great pride that we announce the resounding success of ADN CoE' s AFib Ablation Training program, the second installment in our esteemed Ablation Series, held at the prestigious 9 Eylül University Heart Rhythm Management Centre.

AFIB 52

AFIB Atrial Fibrillation Ablation Heart Rhythm 52

American College of Cardiology

MARCH 8, 2024

PT is an 82-year-old man who presents with persistent, mildly symptomatic atrial fibrillation (AF) of approximately 4-5 months' duration.

Atrial Fibrillation 54

Atrial Fibrillation Electrophysiology Ablation Article 54

DAIC

FEBRUARY 6, 2024

EGF mapping allows physicians to detect EGF sources and is designed to individualize ablation strategies based on underlying pathophysiologic mechanisms to potentially improve outcomes. By guiding ablation therapy, [EGF mapping] can enable clinicians to provide personalized, highly targeted treatment."

Ablation 104

Ablation Atrial Fibrillation AFIB Pulmonary 104

DAIC

FEBRUARY 2, 2024

milla1cf Fri, 02/02/2024 - 17:18 February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. million people in the United States by 2050 and 17.9 million in Europe by 2060.

Electrophysiology 101

Electrophysiology Innovation AFIB Atrial Fibrillation 101

DAIC

OCTOBER 21, 2024

FDA approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation System.

Ablation 52

Ablation Atrial Fibrillation Technology Electrophysiology 52

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction Some previous studies have reported that a first-step ethanol infusion into the vein of Marshall (EIVOM) with touch-up radiofrequency (RF) ablation can facilitate mitral isthmus (MI) block and improves the ablation outcomes in persistent atrial fibrillation (PeAF) patients. 0.78, p  = .006).

Atrial Fibrillation 75

Atrial Fibrillation Ablation Bicuspid/Mitral Tachycardia 75

DAIC

OCTOBER 30, 2024

The PulseSelect Pulsed Field Ablation System, which was FDA approved in December 2023, offers physicians a safe, single-shot solution for pulmonary vein isolation (PVI) while the Affera Sphere-9 catheter enables physician treatment flexibility with its wide area focal design and 9mm lattice tip that can used with an 8.5Fr sheath.

Ablation 52

Ablation AFIB Atrial Fibrillation Atrial Flutter 52

American College of Cardiology

APRIL 24, 2024

PT is an 82-year-old man who presents with persistent, mildly symptomatic atrial fibrillation (AF) of approximately 4-5 months' duration. He also has New York Heart Association (NYHA) class II heart failure with reduced ejection fraction and left ventricular ejection fraction (LVEF) 40%.

Atrial Fibrillation 40

Atrial Fibrillation Electrophysiology Heart Failure Ablation 40

HeartRhythm

APRIL 30, 2024

Surgical Cox-Maze strategy yields favorable outcomes for patients with persistent atrial fibrillation (PeAF).

Atrial Fibrillation 40

Atrial Fibrillation Electrophysiology Ablation Outcomes 40

Journal of Cardiovascular Electrophysiology

OCTOBER 21, 2024

Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF). However, the long-term outcomes and subclinical HF after nonparoxysmal AF ablation in HFpEF patients have not been fully evaluated.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

DAIC

JANUARY 31, 2024

Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific. "The

Ablation 111

Ablation Atrial Fibrillation Anatomy Pulmonary 111

Journal of Cardiovascular Electrophysiology

JANUARY 15, 2024

Abstract Introduction Atrial fibrillation and atrial flutter originating from the donor s heart is a commonly reported complication post heart transplant. Case A 47-year-old male presented with atrial tachycardia 6 months post heart transplant. This arrhythmia was successfully terminated with radiofrequency ablation.

Atrial Fibrillation 40

Atrial Fibrillation Heart Transplant Atrial Flutter Transplant 40

HeartRhythm

APRIL 30, 2024

While the application of artificial intelligence (AI) in cardiovascular medicine is rising especially for wearable, smart and implantable devices, its use in interventional electrophysiology during an atrial fibrillation (AF) catheter ablation procedure is still emerging.

Atrial Fibrillation 40

Atrial Fibrillation Electrophysiology Ablation 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction Earlier studies have shown a clear association between severity of human immunodeficiency virus (HIV) infection and incident atrial fibrillation (AF). We present the long-term outcome of catheter ablation (CA) and electrophysiological characteristics in HIV+ AF patients. vs. 54%, p  < .001],

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Arrhythmia 40

CardiacWire

NOVEMBER 6, 2024

Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.

AFIB 105

AFIB Electrophysiology Ablation Technology 105

Circulation: Arrhythmia and Electrophysiology

DECEMBER 21, 2023

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Inflammation may promote atrial fibrillation (AF) recurrence after catheter ablation. The first dose of the study drug was administered within 4 hours before ablation. mg twice daily or placebo for 10 days. 2.02];P=0.89). 1.99];P=0.55).CONCLUSIONS:Colchicine

Atrial Fibrillation 40

Atrial Fibrillation Ablation Chest Pain Atrial Flutter 40

All About Cardiovascular System and Disorders

OCTOBER 25, 2023

Rate vs Rhythm Control in Atrial Fibrillation Rate vs rhythm control as a management strategy in atrial fibrillation has been a long standing topic for debate. Nearly two thirds in the rhythm control strategy were on amiodarone and only 14 had catheter ablation. Many were not in sinus rhythm or anticoagulated.

Atrial Fibrillation 52

Atrial Fibrillation Heart Failure Ablation Cardiac Arrest 52

HeartRhythm

APRIL 30, 2024

Atypical Atrial Flutter (AAFL) prevalence is increasing due to the escalating Atrial Fibrillation (AF) ablations and cardiac surgeries. We wanted to explore the outcome of the AAFL ablation, considering the recent changes in mapping and ablation.

Atrial Flutter 40

Atrial Flutter Ablation Electrophysiology Atrial Fibrillation 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

The study investigated the outcomes of 400 patients with PAF who underwent an index ablation procedure, while also identifying the predictors associated with recurrence and progression to PersAF. CI, confidence interval; OR, odd ratio; PAF, paroxysmal atrial fibrillation; PersAF, persistent atrial fibrillation; SR, sinus rhythm.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Outcomes 40

Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2024

Despite the relative efficacy of ablation, the risk of AF recurrence is substantial, particularly in patients with persistent AF (perAF). At present we do not have any reliable intra-procedural electrophysiologic predictors of long-term success of AF ablation other than pulmonary vein isolation.

Pulmonary 64

Pulmonary Ablation Atrial Fibrillation Electrophysiology 64

American College of Cardiology

APRIL 24, 2024

The PRO portion of the currently featured PRO/CON debate between Dr. Brian Olshansky and Dr. John Mandrola presents a significant conundrum within the fields of electrophysiology and geriatric cardiology.

Atrial Fibrillation 61

Atrial Fibrillation Heart Failure Electrophysiology Ablation 61

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Objective To evaluate the progression of electrophysiological phenomena in atrial fibrillation (AF) and elucidate the association between the left atrial conduction velocity (LACV) and AF recurrence after pulmonary vein isolation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Electrophysiology 40

Journal of Cardiovascular Electrophysiology

AUGUST 7, 2023

Abstract A vast amount of now well-established clinical and epidemiological data indicates a close, interdependent, and symbiotic association between atrial fibrillation (AF) and heart failure (HF). whether ablation is mandatory or pointless in patients who have HF).

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation Outcomes 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 5, 2023

Abstract Introduction Influence of early atrial fibrillation (AF) ablation, particularly cryoballoon ablation (CBA), on clinical outcome during long-term follow-up has not been clarified. Methods The study included 2605 patients from Korean CBA registry data with follow-up >12 months after de novo CBA.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Kidney Disease 40

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2023

This study investigated myocardial injury and inflammation following pulmonary vein isolation using (1) Standard radiofrequency ablation, (2) very high-power short-duration (vHPSD)-70W, (3) vHPSD-90W, and (4) pulsed-field ablation (PFA). Results Baseline characteristics were well-balanced between groups (age 63.1 ± 10.3 ng/L; p  < .001).

Ablation 40

Ablation Atrial Fibrillation Technology Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

This prospective study investigated ablative therapy techniques as a treatment of paroxysmal atrial fibrillation (AF). After 12 months of follow-up, there was an 81% freedom of AF in general, which was significantly higher in patients treated with robotic magnetic navigation-guided radiofrequency ablation (RMN-RF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Article 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

FAAM ablation successfully decreased the recurrence rate of atrial tachyarrhythmia compared with conventional non-PV foci ablation. Abstract Introduction Treatment of recurrent atrial fibrillation (AF) is sometimes challenging due to non-pulmonary vein (PV) foci.

Ablation 40

Ablation Atrial Fibrillation Atrial Flutter Tachycardia 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction Catheter ablation of atrial fibrillation (AF) has emerged as the most effective therapy. However, rare anatomical abnormalities such as situs inversus totalis, dextrocardia, or interrupted inferior vena cava can make ablation challenging.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pacemaker Technology 40

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction The optimized ablation index (AI) value for catheter ablation of atrial fibrillation (AF) remains to be defined. Methods and Results Patients with symptomatic, drug-resistant paroxysmal AF for first ablation were prospectively enrolled from September 2020 to January 2022.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 8, 2023

Abstract Background Incomplete atrial lesions resulting in pulmonary vein-left atrium reconnection after pulmonary vein antrum isolation (PVAI), are related to atrial fibrillation (AF) recurrence. Results The PVAI-L was visible in 10 patients (100%) using 3D-TWILITE and 3D-LGE.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Article 40

Journal of Cardiovascular Electrophysiology

JANUARY 10, 2024

Abstract Introduction Despite advanced ablation strategies and major technological improvements, treatment of persistent atrial fibrillation (AF) remains challenging and the underlying pathophysiology is not fully understood. ms after) and AF termination to atrial tachycardia (AT) or sinus rhythm (SR) in 12 patients (24%).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outpatient Arrhythmia 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction The prospective, nonrandomized, multicenter Q-FFICIENCY study demonstrated the safety and 12-month efficacy of paroxysmal atrial fibrillation (AF) ablation with the novel QDOT MICRO temperature-controlled, contact force-sensing, radiofrequency (RF) catheter. 86.9%) and 88.8% (95% CI, 84.0%–93.7%),

Atrial Fibrillation 40

Atrial Fibrillation Ablation Quality of Life Hospital 40

HeartRhythm

MAY 15, 2024

In the past decade, major advances were made in catheter ablation for arrhythmias and implantation of cardiac implantable electronic devices.1 1 Catheter ablation for atrial fibrillation (AF) and ventricular tachycardia (VT) has become the standard of care for many patients presenting with these arrhythmias.2–4

Electrophysiology 40

Electrophysiology Atrial Fibrillation Ablation Arrhythmia 40